Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 2
2013 2
2014 2
2015 1
2019 2
2020 1
2021 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
10-Year Results of FLEx Refractive Surgery.
Blum M, Kunert KS, Schulze M, Sekundo W. Blum M, et al. Among authors: schulze m. J Refract Surg. 2019 Nov 1;35(11):707-711. doi: 10.3928/1081597X-20191002-01. J Refract Surg. 2019. PMID: 31710372 Clinical Trial.
(E)-2-[2-(3-Nitro-phen-yl)ethen-yl]quinolin-8-ol.
Schulze M, Seichter W, Weber E. Schulze M, et al. Acta Crystallogr Sect E Struct Rep Online. 2013 Oct 16;69(Pt 11):o1651-2. doi: 10.1107/S1600536813027815. eCollection 2013 Oct 16. Acta Crystallogr Sect E Struct Rep Online. 2013. PMID: 24454092 Free PMC article.
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315).
Griesinger F, Sebastian M, Brueckl WM, Hummel HD, Jaeschke B, Kern J, Wesseler C, Jänicke M, Fleitz A, Zacharias S, Hipper A, Groth A, Weichert W, Dörfel S, Petersen V, Schröder J, Wilke J, Eberhardt WEE, Thomas M; CRISP Registry Group. Griesinger F, et al. JTO Clin Res Rep. 2023 Dec 25;5(4):100626. doi: 10.1016/j.jtocrr.2023.100626. eCollection 2024 Apr. JTO Clin Res Rep. 2023. PMID: 38586301 Free PMC article.
Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study.
Stein A, Petersen V, Schulze M, Seraphin J, Hoeffkes HG, Valdix AR, Schroeder J, Herrenberger J, Boxberger F, Leutgeb B, Hinke A, Kutscheidt A, Arnold D. Stein A, et al. Among authors: schulze m. Acta Oncol. 2015 Feb;54(2):171-8. doi: 10.3109/0284186X.2014.961649. Epub 2014 Oct 13. Acta Oncol. 2015. PMID: 25307517
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermüller J, Haberl C, Schalhorn A, Jung A, Stintzing S, Heinemann V. Moosmann N, et al. Among authors: schulze m. J Clin Oncol. 2011 Mar 10;29(8):1050-8. doi: 10.1200/JCO.2010.31.1936. Epub 2011 Feb 7. J Clin Oncol. 2011. PMID: 21300933 Clinical Trial.
11 results